We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HELP
101
Cybin Inc
HELP
$490M
$8.6M 0.14%
276,955
– –
ELVN icon
102
Enliven Therapeutics
ELVN
$3.78B
$8.25M 0.13%
1,096,642
– –
IRON icon
103
Disc Medicine
IRON
$2.82B
$8.1M 0.13%
194,207
– –
LENZ
104
LENZ Therapeutics
LENZ
$179M
$7.99M 0.13%
223,687
– –
RAPT
105
DELISTED
RAPT Therapeutics
RAPT
$7.95M 0.13%
45,163
+18,038
+66% +$3.41M
SONX
106
DELISTED
Sonendo, Inc.
SONX
$7.89M 0.13%
1,968,180
– –
CGEM icon
107
Cullinan Oncology
CGEM
$1.06B
$7.02M 0.11%
670,787
-134,254
-17% -$1.81M
SYRE icon
108
Spyre Therapeutics
SYRE
$8.5B
$6.8M 0.11%
118,245
– –
DNTH icon
109
Dianthus Therapeutics
DNTH
$5.69B
$6.53M 0.11%
140,685
– –
NMTR
110
DELISTED
9 Meters Biopharma
NMTR
$6.16M 0.1%
513,794
– –
NTRA icon
111
CALL
Natera
NTRA
$36.3B
$6.1M 0.1%
+150,000
New +$9.01M
ALBO
112
DELISTED
Albireo Pharma Inc
ALBO
$5.79M 0.09%
+194,000
New +$5.68M
LOGC
113
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$5.76M 0.09%
8,466,783
– –
CTMX icon
114
CytomX Therapeutics
CTMX
$690M
$5.67M 0.09%
2,124,975
-1,089,534
-34% -$4.18M
PHGE icon
115
BiomX
PHGE
$1.94M
$5.43M 0.09%
14,808
– –
IMDX
116
Insight Molecular Diagnostics
IMDX
$140M
$5.21M 0.08%
174,690
– –
CALC icon
117
CalciMedica
CALC
$11.7M
$5.12M 0.08%
297,382
– –
VOR icon
118
Vor Biopharma
VOR
$1.06B
$5.03M 0.08%
41,667
– –
ACHL
119
DELISTED
Achilles Therapeutics
ACHL
$4.66M 0.08%
1,584,845
– –
TARA icon
120
Protara Therapeutics
TARA
$215M
$4.25M 0.07%
830,641
– –
IMCR icon
121
Immunocore
IMCR
$1.7B
$3.83M 0.06%
+128,100
New +$3.23M
AFIB
122
DELISTED
Acutus Medical Inc
AFIB
$3.68M 0.06%
2,648,386
– –
SRPT icon
123
Sarepta Therapeutics
SRPT
$1.64B
$3.05M 0.05%
39,100
-19,600
-33% -$1.5M
VIGL
124
DELISTED
Vigil Neuroscience
VIGL
$2.89M 0.05%
+411,191
New +$5.43M
TRML
125
DELISTED
Tourmaline Bio
TRML
$2.43M 0.04%
24,724
– –
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.